Arcturus Therapeutics is trading at $9.84, down 9.15%, with the specific catalyst unclear. - No verified company-specific announcement explaining the November 5 decline surfaced in the search. - Arcturus had scheduled its Q3 results and corporate update for after the market close on November 5, so they were not available at 10:14 a.m. - The supplied context reports a biotech-sector gain, which does not explain the stock’s drop.